Submission of the 38th Annual Report including Notice of AGM of Company for the FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals Limited has filed its 38th Annual Report for FY 2024-25 with BSE, along with the notice for its 38th AGM scheduled for September 30, 2025 at 9:00 AM via video conferencing. Key agenda items include adoption of audited financial statements and declaration of a 7% dividend on equity shares for FY 2024-25. Shareholders will also vote on the re-appointment of Managing Director Fredun Nariman Medhora, ratification of cost auditor remuneration of Rs. 1.25 lakh, and approval of related party transactions up to Rs. 1 crore per transaction. The notice seeks approval for appointing two new Independent Directors — Mr. Anshu Agarwal and Ms. Sonal Dharmin Desai — for five-year terms ending in 2030, and the appointment of Ms. Kala Agarwal as Secretarial Auditor for FY 2025-26 to 2029-30. The company's MD message highlights expansion into pet care, veterinary diagnostics (Fredna Vet Diagnostics), consumer wellness (Chuu Balm), and the acquisition of One Pet Stop Pvt Ltd, alongside a roadmap to move from contract manufacturing to branded generics through 'Fredun Gx'.
The 7% dividend declaration is a positive income signal for shareholders, while the strategic diversification into pet care, nutraceuticals, and consumer wellness signals the company's intent to reduce reliance on core pharma. Shareholders should note the sad demise of Non-Executive Director Mr. Nariman Medhora in June 2025, though the proposed addition of two qualified independent directors supports governance continuity.